AZD2281

AZD2281

AZD2281 (pronounced as A-Z-D-two-two-eight-one), also known as Olaparib, is a pharmaceutical drug used in the treatment of certain types of cancer. It is a type of PARP inhibitor, which stands for Poly (ADP-ribose) polymerase inhibitor.

Etymology

The name AZD2281 is derived from the code assigned to it during its development phase by the pharmaceutical company AstraZeneca. The name Olaparib follows the World Health Organization's International Nonproprietary Naming (INN) system, where 'parib' is a common stem for PARP inhibitors.

Usage

AZD2281 is used in the treatment of certain types of ovarian cancer, breast cancer, and pancreatic cancer. It is specifically used in patients with a mutated BRCA gene, as the drug works by inhibiting the PARP enzyme, which is involved in DNA repair. By inhibiting this enzyme, the drug prevents cancer cells from repairing their DNA, leading to cell death.

Related Terms

• Pharmaceutical drug
• Cancer
• PARP inhibitor
• Ovarian cancer
• Breast cancer
• Pancreatic cancer
• BRCA gene
• DNA repair
• Cell death

External links

• Medical encyclopedia article on AZD2281
• Wikipedia's article - AZD2281

This WikiMD dictionary article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski